<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37147581</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2369</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>BMC nephrology</Title><ISOAbbreviation>BMC Nephrol</ISOAbbreviation></Journal><ArticleTitle>Atypical haemolytic uremic syndrome with refractory multiorgan involvement and heterozygous CFHR1/CFHR3 gene deletion.</ArticleTitle><Pagination><StartPage>127</StartPage><MedlinePgn>127</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12882-023-03153-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">We present this challenging case report of Atypical Haemolytic Uremic Syndrome (aHUS) presenting with multi-organ involvement in a patient and heterozygous CFHR1/CFHR3 gene variant, which was refractory to initial eculizumab therapy.</AbstractText><AbstractText Label="CASE PRESENTATION">A forty-three year old female presented with aHUS and had heterozygous disease-associated deletions in the complement genes CFHR1/CFHR3. She had progressive kidney failure and severe extra-renal manifestations including cardiomyopathy and haemorrhagic cystitis; as well as pulmonary, gastrointestinal and neurological involvement. The initial kidney biopsy revealed thrombotic microangiopathy (TMA) changes involving all glomeruli. Clinical improvement was initially seen during eculizumab initiation with suppressed CH50 level, but a new rhinovirus/enterovirus upper respiratory tract infection triggered further severe multi-organ disease activity. The extra-renal manifestations stabilised, then ultimately improved after a period of eculizumab dose intensification. However, the impact on dose intensification on this improvement is unclear. Despite the extra-renal clinical improvement, she ultimately progressed to end-stage kidney disease (ESKD), commencing peritoneal dialysis for three years before undergoing a successful uncomplicated cadaveric kidney transplant without prophylactic eculizumab. Two years after transplant, she has excellent transplant graft function without any further disease recurrence.</AbstractText><AbstractText Label="CONCLUSIONS">This case highlights the concept of extra-renal manifestations in aHUS initially resistant to eculizumab, which potentially responded to dose intensification. Whilst organ injuries are potentially reversible with timely targeted treatment, it appears that the kidneys are most vulnerable to injury.</AbstractText><CopyrightInformation>© 2023. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diep</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2447-3035</Identifier><AffiliationInfo><Affiliation>Department of Renal Medicine, Liverpool Hospital, Locked Bag 7103, Liverpool, BC NSW 1871, Australia. diep.jason@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia. diep.jason@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Renal Medicine, Liverpool Hospital, Locked Bag 7103, Liverpool, BC NSW 1871, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Renal Medicine, Liverpool Hospital, Locked Bag 7103, Liverpool, BC NSW 1871, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Haematology, Liverpool Hospital, Liverpool, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Nephrol</MedlineTA><NlmUniqueID>100967793</NlmUniqueID><ISSNLinking>1471-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105970">CFHR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001798">Blood Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517621">CFHR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003180">Complement C3b Inactivator Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065766" MajorTopicYN="Y">Atypical Hemolytic Uremic Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001798" MajorTopicYN="N">Blood Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003180" MajorTopicYN="N">Complement C3b Inactivator Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute kidney injury</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">End-stage kidney disease</Keyword><Keyword MajorTopicYN="N">Haemolytic uremic syndrome</Keyword><Keyword MajorTopicYN="N">Kidney transplant</Keyword><Keyword MajorTopicYN="N">Thrombotic microangiopathy</Keyword></KeywordList><CoiStatement>DH has received speaking honoraria and advisory board participation with Alexion Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>6</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>5</Day><Hour>23</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37147581</ArticleId><ArticleId IdType="pmc">PMC10161558</ArticleId><ArticleId IdType="doi">10.1186/s12882-023-03153-x</ArticleId><ArticleId IdType="pii">10.1186/s12882-023-03153-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi: 10.1186/1750-1172-6-60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-6-60</ArticleId><ArticleId IdType="pmc">PMC3198674</ArticleId><ArticleId IdType="pubmed">21902819</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhouri F, et al. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681–696. doi: 10.1016/S0140-6736(17)30062-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30062-4</ArticleId><ArticleId IdType="pubmed">28242109</ArticleId></ArticleIdList></Reference><Reference><Citation>Fremeaux-Bacchi V, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554–562. doi: 10.2215/CJN.04760512.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04760512</ArticleId><ArticleId IdType="pmc">PMC3613948</ArticleId><ArticleId IdType="pubmed">23307876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheerin NS, et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM. 2016;109(1):27–33. doi: 10.1093/qjmed/hcv082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcv082</ArticleId><ArticleId IdType="pubmed">25899302</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnappa V, et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018;22(2):178–188. doi: 10.1111/1744-9987.12641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1744-9987.12641</ArticleId><ArticleId IdType="pubmed">29250893</ArticleId></ArticleIdList></Reference><Reference><Citation>Legendre CM, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–2181. doi: 10.1056/NEJMoa1208981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1208981</ArticleId><ArticleId IdType="pubmed">23738544</ArticleId></ArticleIdList></Reference><Reference><Citation>Willrich MAV, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63–71. doi: 10.1016/j.jim.2018.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2018.06.010</ArticleId><ArticleId IdType="pubmed">29935209</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijnsma KL, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859–874. doi: 10.1007/s40262-019-00742-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-019-00742-8</ArticleId><ArticleId IdType="pmc">PMC6584251</ArticleId><ArticleId IdType="pubmed">30758736</ArticleId></ArticleIdList></Reference><Reference><Citation>Peffault de Latour R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775–83. doi: 10.1182/blood-2014-03-560540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-560540</ArticleId><ArticleId IdType="pubmed">25477495</ArticleId></ArticleIdList></Reference><Reference><Citation>Jodele S, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(2):307–315. doi: 10.1016/j.bbmt.2015.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2015.10.002</ArticleId><ArticleId IdType="pmc">PMC4716886</ArticleId><ArticleId IdType="pubmed">26456258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura J, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639. doi: 10.1056/NEJMoa1311084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1311084</ArticleId><ArticleId IdType="pubmed">24521109</ArticleId></ArticleIdList></Reference><Reference><Citation>Risitano AM, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi: 10.3389/fimmu.2019.01157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01157</ArticleId><ArticleId IdType="pmc">PMC6587878</ArticleId><ArticleId IdType="pubmed">31258525</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J Biol Chem. 1998;273(27):16828–35. doi: 10.1074/jbc.273.27.16828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.27.16828</ArticleId><ArticleId IdType="pubmed">9642242</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem. 2003;278(40):38476–38483. doi: 10.1074/jbc.M307017200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M307017200</ArticleId><ArticleId IdType="pubmed">12878586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal N, Pangburn M. Formation of high-affinity C5 convertases of the alternative pathway of complement. J Immunol. 2001;166(4):2635–2642. doi: 10.4049/jimmunol.166.4.2635.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.166.4.2635</ArticleId><ArticleId IdType="pubmed">11160326</ArticleId></ArticleIdList></Reference><Reference><Citation>Jodele S, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645–653. doi: 10.1182/blood-2014-03-564997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-564997</ArticleId><ArticleId IdType="pmc">PMC4110664</ArticleId><ArticleId IdType="pubmed">24876561</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskin BL, et al. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2011;46(5):682–689. doi: 10.1038/bmt.2010.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2010.182</ArticleId><ArticleId IdType="pubmed">20697372</ArticleId></ArticleIdList></Reference><Reference><Citation>Togitani K, et al. Thrombotic microangiopathy of hyperacute onset after autologous peripheral blood stem cell transplantation in malignant lymphoma. Bone Marrow Transplant. 1998;21(12):1263–1266. doi: 10.1038/sj.bmt.1701260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1701260</ArticleId><ArticleId IdType="pubmed">9674861</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92(5):1471–1490. doi: 10.1182/blood.V92.5.1471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V92.5.1471</ArticleId><ArticleId IdType="pubmed">9716573</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014;10(3):174–180. doi: 10.1038/nrneph.2013.280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2013.280</ArticleId><ArticleId IdType="pubmed">24419569</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary P, et al. Atypical haemolytic-uraemic syndrome due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. Blood Transfus. 2014;12(1):111–113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3926711</ArticleId><ArticleId IdType="pubmed">24333077</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel PF, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3(3):e41. doi: 10.1371/journal.pgen.0030041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0030041</ArticleId><ArticleId IdType="pmc">PMC1828695</ArticleId><ArticleId IdType="pubmed">17367211</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris M, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. doi: 10.2215/CJN.02210310.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02210310</ArticleId><ArticleId IdType="pmc">PMC2974386</ArticleId><ArticleId IdType="pubmed">20595690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>